Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)

Trial Profile

Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs BI 655130 (Primary)
  • Indications Palmoplantar pustulosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 14 Nov 2017 Planned End Date changed from 29 Jun 2018 to 31 Aug 2018.
    • 14 Nov 2017 Planned primary completion date changed from 9 Mar 2018 to 11 May 2018.
    • 05 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top